103,651 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Aviva PLC

Aviva PLC bought a new position in Exact Sciences Co. (NASDAQ:EXAS) during the fourth quarter, Holdings Channel reports. The firm bought 103,651 shares of the medical research company’s stock, valued at approximately $5,824,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Asset Planning Inc bought a new stake in shares of Exact Sciences in the 4th quarter worth approximately $40,000. Modus Advisors LLC bought a new stake in shares of Exact Sciences in the 4th quarter worth approximately $43,000. AlphaQuest LLC raised its holdings in shares of Exact Sciences by 22,825.0% in the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after purchasing an additional 913 shares during the period. SBI Securities Co. Ltd. bought a new stake in shares of Exact Sciences in the 4th quarter worth approximately $66,000. Finally, Kieckhefer Group LLC bought a new stake in shares of Exact Sciences in the 4th quarter worth approximately $188,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Upgrades and Downgrades

EXAS has been the subject of a number of recent research reports. Piper Sandler reduced their price objective on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Scotiabank lifted their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Benchmark reiterated a “buy” rating and issued a $65.00 price objective on shares of Exact Sciences in a research note on Monday, January 13th. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 20th. Finally, Bank of America reduced their price target on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Two research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $70.26.

Exact Sciences Price Performance

EXAS stock opened at $45.50 on Thursday. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $73.81. The company has a market cap of $8.45 billion, a P/E ratio of -8.17 and a beta of 1.14. The firm has a 50-day moving average of $47.38 and a 200 day moving average of $56.14. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. On average, sell-side analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.